Nutrition 21, headquartered in Purchase, NY, is a nutritional bioscience company and holds over 60 issued and pending patents for dietary supplement ingredients, including chromium picolinate and combinations of chromium compounds with other ingredients.
Nutrition 21 R&D vice president James Komorowski said that they are very excited to receive the financial support to advance the development of their technology surrounding a novel chromium-enhanced insulin drug that may reduce the risk and symptoms of hypoglycemia, reduce weight gain caused by insulin use, and be more effective than insulin drugs currently on the market.
"We are grateful that the QTDP Program recognised the potential of this novel technology and awarded us this grant," Komorowski said.
Nutrition 21 president and CEO Michael Zeher said that this grant demonstrates recognition of the technology the company is developing.
"Since the QTDP process is rigorous, we’re particularly gratified that we were approved," Zeher said.